163 related articles for article (PubMed ID: 7627993)
1. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
2. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
5. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
6. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
[TBL] [Abstract][Full Text] [Related]
7. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
8. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?
Fagerberg J; Frödin JE; Ragnhammar P; Steinitz M; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1994 Mar; 38(3):149-59. PubMed ID: 8124683
[TBL] [Abstract][Full Text] [Related]
9. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?
Frödin JE; Faxas ME; Hagström B; Lefvert AK; Masucci G; Nilsson B; Steinitz M; Unger P; Mellstedt H
Hybridoma; 1991 Aug; 10(4):421-31. PubMed ID: 1937495
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody CO17-1A in animals and patients.
Herlyn D; Harris D; Zaloudik J; Sperlagh M; Maruyama H; Jacob L; Kieny MP; Scheck S; Somasundaram R; Hart E
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):303-11. PubMed ID: 8061902
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).
Ragnhammar P; Magnusson I; Masucci G; Mellstedt H
Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997
[TBL] [Abstract][Full Text] [Related]
12. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Ljungberg A; Hjelm AL; Fagerberg J; Lindemalm C; Osterborg A; Wersäll P
Acta Oncol; 1991; 30(8):923-31. PubMed ID: 1777244
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
14. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
Fagerberg J; Frödin JE; Wigzell H; Mellstedt H
Cancer Immunol Immunother; 1993 Sep; 37(4):264-70. PubMed ID: 8348565
[TBL] [Abstract][Full Text] [Related]
15. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.
Wettendorff M; Iliopoulos D; Tempero M; Kay D; DeFreitas E; Koprowski H; Herlyn D
Proc Natl Acad Sci U S A; 1989 May; 86(10):3787-91. PubMed ID: 2786203
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and immunotherapy of colorectal cancer.
Masucci G; Ragnhammar P; Frödin JE; Hjelm AL; Wersäll P; Fagerberg J; Osterborg A; Mellstedt H
Med Oncol Tumor Pharmacother; 1991; 8(3):207-20. PubMed ID: 1803182
[TBL] [Abstract][Full Text] [Related]
18. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
19. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
20. Modulation of cancer patients' immune responses by anti-idiotypic antibodies.
Herlyn D; Wettendorff M; Koprowski H
Int Rev Immunol; 1989; 4(4):347-57. PubMed ID: 2519932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
